- Home
- MDAI vs MREO Comparison
MDAI vs MREO Comparison
Compare MDAI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDAI | MREO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United Kingdom |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 50.3M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MDAI | MREO |
|---|---|---|
| Price | $1.52 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | ★ $5.11 | $1.97 |
| AVG Volume (30 Days) | 110.0K | ★ 624.0K |
| Earning Date | 11-10-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.88 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,650,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $74.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $0.20 |
| 52 Week High | $2.97 | $2.37 |
Technical Indicators
Market Signals| Indicator | MDAI | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 42.10 |
| Support Level | $1.42 | $0.27 |
| Resistance Level | $1.48 | $0.35 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 36.00 | 20.85 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).